DNMT3A and acute myeloid leukemia: By comparing the clinical parameters between the two groups, we found that AML patients carrying DNMT3A R882 mutations also exhibited higher peripheral blood cell levels (WBC 46.9*109/L vs. 13*109/L, 99 g/L vs. 80 g/L, and Plt 113.2*109/L vs. 43*109/L) compared with those in the DNMT3A frameshift group.